PubMed (MeSH Keyword) for id: 135659042

Year	Number of Results
2011	1
2013	2
2014	3
2015	7
2016	2
2017	3
2018	5
2019	2
2020	1
2021	2
2022	3
2024	0

1

Anti-Inflammatory Effect of Sparstolonin B through Inhibiting Expression of NF-κB and STAT-1.

Kim N, Kim C, Ryu SH, Kim GO, Bae JS. Kim N, et al. Int J Mol Sci. 2022 Sep 6;23(18):10213. doi: 10.3390/ijms231810213. Int J Mol Sci. 2022. PMID: 36142124 Free PMC article.

2

Sparstolonin B inhibits pancreatic adenocarcinoma through the NF-κB signaling pathway.

Lyu Y, Duan B, Liu Z, Yang F, Chen C, Jiang X, Liu X. Lyu Y, et al. Exp Cell Res. 2022 Aug 1;417(1):113214. doi: 10.1016/j.yexcr.2022.113214. Epub 2022 May 18. Exp Cell Res. 2022. PMID: 35594953

3

Sparstolonin B suppresses free fatty acid palmitate-induced chondrocyte inflammation and mitigates post-traumatic arthritis in obese mice.

Ma H, Xie C, He G, Chen Z, Lu H, Wu H, Cai H, Dai Z, Li B, Xu C, Xue E. Ma H, et al. J Cell Mol Med. 2022 Feb;26(3):725-735. doi: 10.1111/jcmm.17099. Epub 2021 Dec 24. J Cell Mol Med. 2022. PMID: 34953038 Free PMC article.

4

Sparstolonin B exerts beneficial effects on prostate cancer by acting on the reactive oxygen species-mediated PI3K/AKT pathway.

Liu S, Hu J, Shi C, Sun L, Yan W, Song Y. Liu S, et al. J Cell Mol Med. 2021 Jun;25(12):5511-5524. doi: 10.1111/jcmm.16560. Epub 2021 May 5. J Cell Mol Med. 2021. PMID: 33951324 Free PMC article.

5

Toll-like receptor involvement in adolescent scoliotic facet joint degeneration.

Bisson DG, Sheng K, Kocabas S, Krock E, Teles A, Saran N, Ouellet JA, Haglund L. Bisson DG, et al. J Cell Mol Med. 2020 Oct;24(19):11355-11365. doi: 10.1111/jcmm.15733. Epub 2020 Aug 27. J Cell Mol Med. 2020. PMID: 32853438 Free PMC article.

6

Altered Toll-Like Receptor Signalling in Children with Down Syndrome.

Huggard D, Koay WJ, Kelly L, McGrane F, Ryan E, Lagan N, Roche E, Balfe J, Leahy TR, Franklin O, Moreno-Oliveira A, Melo AM, Doherty DG, Molloy EJ. Huggard D, et al. Mediators Inflamm. 2019 Sep 12;2019:4068734. doi: 10.1155/2019/4068734. eCollection 2019. Mediators Inflamm. 2019. PMID: 31611734 Free PMC article.

7

Sparstolonin B: A Unique Anti-Inflammatory Agent.

Yepuri N, Dhawan R, Cooney M, Pruekprasert N, Meng Q, Cooney RN. Yepuri N, et al. Shock. 2019 Dec;52(6):568-576. doi: 10.1097/SHK.0000000000001326. Shock. 2019. PMID: 30807526 Review.

8

Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Dattaroy D, Seth RK, Sarkar S, Kimono D, Albadrani M, Chandrashekaran V, Hasson FA, Singh UP, Fan D, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Dattaroy D, et al. Eur J Pharmacol. 2018 Dec 15;841:33-48. doi: 10.1016/j.ejphar.2018.08.040. Epub 2018 Sep 5. Eur J Pharmacol. 2018. PMID: 30194936 Free PMC article.

9

Sparstolonin B attenuates spinal cord injury‑induced inflammation in rats by modulating TLR4‑trafficking.

Yuan J, Zhang X, Zhu R, Cui Z, Hu W. Yuan J, et al. Mol Med Rep. 2018 Apr;17(4):6016-6022. doi: 10.3892/mmr.2018.8561. Epub 2018 Feb 6. Mol Med Rep. 2018. PMID: 29436632

10

Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis.

Tang YM, Cao QY, Guo XY, Dong SH, Duan JA, Wu QN, Liang QL. Tang YM, et al. Biomed Pharmacother. 2018 Feb;98:382-389. doi: 10.1016/j.biopha.2017.12.047. Epub 2017 Dec 27. Biomed Pharmacother. 2018. PMID: 29276966

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

26 results

Results by year